 |
Cholest-4-en-3-one, oxime |
|---|---|
| Trade Name | |
| Orphan Indication | Spinal muscular atrophy |
| EU Market Approval | EU |
| EU Designation Date | 2005-03-10 00:00:00 |
| Sponsor | Roche Registration Limited |
Related Access Program
Pfizer – Non Small Cell Lung Cancer With ALK or ROS1 Rearrangement
Pfizer – Non Small Cell Lung Cancer Harboring Molecular Alterations
Biogen – Infantile-onset Spinal Muscular Atrophy
Novartis Pharmaceuticals – Non-small Cell Lung Cancer (NSCLC)
Biogen – Infantile-onset Spinal Muscular Atrophy (SMA)